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We report on 254 consecutive patients (170 male, 84 female) undergoing 
aortic valve replacement with the Toronto SPV Stentless Valve (St. Jude 
Medical, Inc., St. Paul, Minn.). Mean age ( -  standard deviation) was 
62.1 - 11.6 years. Three patients (1%) received sizes 21 or 22 mm, 24 (9%) 
received size 23 mm, and 227 patients (89%) received sizes 25, 27, or 29 mm. 
Serial echocardiography was used to assess valve performance during a 
3-year follow-up. Mean gradient decreased by 35.8% (p < 0.0001; 95% 
confidence interval -39.6%, -31.7%) from postoperative alues to the 3- to 
6-month follow-up and by 6.1% (p = 0.004; 95% confidence interval -10.1%, 
-2%) at each subsequent interval; effective orifice area increased by 17.2% 
(p -- 0.0001; 95% confidence interval 12.0%, 22.6%) initially and by 4.4% (p < 
0.001; 95% confidence interval 1.8%, 7.0%) thereafter. At 2 years of follow-up, 
mean gradient was 3.3 -+ 2.1 mm Hg and mean effective orifice area was 2.2 _ 
0.8 cm 2. Studies on left ventricular mass were carried out on 84 patients. Left 
ventricular mass decreased by 14.3% (37.8 --- 57.9 gm; p < 0.0001; 95% 
confidence interval --53,7, -21.9 gin) and left ventricular mass index de- 
creased by 15.2% (21.1 - 30.5 gm/m2; p < 0.0001; 95% confidence interval 
-29.5, -12.7 gm/m 2) from postoperative alues to the 3- to 6-month follow-up 
interval. The reduction in residual gradient and potential regression in left 
ventricular hypertrophy may have a beneficial prognostic implication. We 
believe that the unique stenfless design of the Toronto SPV Stentless Valve 
allows this to occur. (J Thorac Cardiovasc Surg 1996;112:1431-46) 
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C ardiac myocytes, unlike cells from other organs, proliferate only in the fetal period; soon after 
birth they lose their ability to replicate deoxyribo- 
nucleic acid. I' 2 However, adaptive growth of the 
heart must still occur in response to physiologic 
demands and pathologic states that increase cardiac 
work)  Postnatal cardiac development must there- 
fore maintain proper allometric ratio of heart to 
body size and also allow matching of heart size to 
functional oad during adaptation to altered hemo- 
dynamic requirements. 
Ventricular hypertrophy is a physiologic response to 
an altered hemodynamic state; it can occur in several 
pathological conditions including valvular heart dis- 
ease. The hypertrophic response is mediated by classic 
signal transduction mechanisms, 1' 2, 4-7 with activation 
of a specific family of genes ' 9 that function as medi- 
ators of long term cellular responses. 4 The salient 
feature of transduction pathways is that the signal 
mechanisms must be sustained to maintain the pro- 
cess. 
Aortic valvular disease is known to produce left 
ventricular hypertrophy (LVH). If signal transduc- 
tion mechanisms are operational in the induction of 
LVH in human beings, then correction of the valve 
lesion, although it may alleviate symptoms, may not 
necessarily result in regression of LVH if a residual 
gradient exists. We have observed that transvalvular 
gradients decrease with time in patients who un- 
dergo aortic valve replacement (AVR) with a To- 
ronto SPV Stentless Valve (SPV; St. Jude Medical, 
Inc., St. Paul, Minn.). The initial clinical results on 
this group of patients are reported elsewhere. 1° In 
this report, we focus on the hemodynamic changes 
to support he hypothesis that ventricular remodel- 
ing occurs after AVR with a stentless bioprosthesis. 
Materials and methods 
Patient population. In this cohort, 254 patients under- 
went AVR (with or without concomitant coronary bypass) 
with the SPV before December 31, 1995. For this report, 
the implanting centers were Sunnybrook Health Science 
Center (N = 84 patients) and Toronto Hospital (N = 170 
patients) in Toronto, Ontario, Canada. All patients are 
part of an international phase II, multicenter, prospective 
clinical trial to assess the safety and efficacy of the SPV. 
Clinical patient characteristics are summarized inTable I. 
Study valve. The SPV is a stentless porcine valve 
manufactured bySt. Jude Medical (St. Paul, Minn.). It is 
an excised porcine aortic valve fixed in glutaraldehyde 
under low pressure. The SPV comprises only the valve and 
sufficient aortic wall tissue to support he commissures 
and leaflets. It is covered with a single layer of fine Dacron 
polyester fabric. TM 12 Three colored sutures are placed at 
the base of the inflow at 120 degrees intervals to facilitate 
implantation. The SPVs were implanted with a technique 
that is similar to that originally described by Ross 13 for 
freehand homografts and has been previously de- 
scribed.12, 14 
Echocardiography. All patients who underwent AVR 
with an SPV were followed up with serial echocardiogra- 
phy. The first examination was performed early in the 
immediate postoperative p riod, usually just before dis- 
charge. Subsequent follow-up examinations were done 
between 3 and 6 months, at 1 year, and annually thereaf- 
ter. Transthoracic echocardiographic analysis of the leaf- 
lets and the left ventricular outflow tract (LVOT) and 
continuous-wave and color Doppler studies were per- 
formed at each examination and used to assess valve 
function. 
Statistical methods. Data from each center participat- 
ing in the ongoing clinical trial were collected and ana- 
lyzed by St. Jude Medical. Statistical analyses were per- 
formed with SAS (Statistical Analysis System, Cary, N.C.) 
and BMDP 5V statistical software packages (SPSS Inc., 
Chicago, Ill.). Discrete variables are presented as counts 
and percentages. Continuous variables are presented as 
means (-+ standard eviation). Formulas for calculating 
mean systolic gradient, effective orifice area (EOA), and 
left ventricular mass are provided in the Appendix. Sta- 
tistical significance was at the nominal c~ level of 0.05. 
Mean gradient and EOA were modeled with the longi- 
tudinal methods of Laird and Ware. 15 For each response, 
logs of the five serial measurements for a patient (early 
postoperative period, 3 to 6 months, 12 months, 24 
months, and 36 months) were assumed to be an approxi- 
mately multivariate normal vector with general covariance 
structure. The Laird-Ware method permits missing data. 
Means in the log scale for each period are estimated, 
adjusting for the observed patterns of missing data, mak- 
ing use of the correlation among the longitudinal obser- 
vations. Means (in the log scale) were estimated sepa- 
rately for each size. Regression models were used to 
estimate the amount of change in the measurement from 
early postoperative p riod to 3 to 6 months and the trend 
in changes from 3 to 6 months to 3 years. The covariates 
were evaluated for importance singly and in combination 
by means of stepwise procedures. Arithmetic means in the 
log scale transform back to geometric means in the 
original scale. Plots of the estimated medians (with asso- 
ciated confidence limits) are provided. 
For complication rates, both the simple percentage of
patients with early events (<30 days) and linearized rates 
for late events (>30 days) are reported. Linearized rates 
(in percent per patient-year) were calculated by dividing 
the number of events by patient-years of follow-up and 
multiplying by 100%. Survival was determined by the 
Kaplan-Meier product limit method. 16 The number of 
patients at risk is shown for each interval, along with 95% 
confidence limits for the estimates. 
Data on left ventricular mass were obtained from 
patients who were operated on at the Sunnybrook Health 
Science Centre (N = 84). All left ventricular mass and 
gradient data for this subset were analyzed with the advice of 
the Department of Research Design and Biostatistics, Sun- 
nybrook Health Science Centre, University of Toronto, 
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Fig. 1. Actuarial survival was determined by the Kaplan-Meier method. The number of patients at risk is 
shown along the x-axis. At 3 years after operation, survival was 95%. 
Toronto, Canada. The initial change from postoperative 
period to the 3 to 6 month interval for the continuous 
variables (peak and mean gradient, EOA, thickness of 
intraventricular septum, posterior left ventricular wall thick- 
ness, left ventricular mass, and left ventricular mass index) 
was tested by matched pairs t test. Further analysis of left 
ventricular mass and gradient with time up to the 1-year 
interval was performed in two steps. Initially, a multivariate 
analysis of variance of both left ventricular mass and gradient 
up to the 1-year interval was applied to establish the statis- 
tical significance ofthe overall effect of time on both of the 
primary dependent variables (gradient and left ventricular 
mass) considered.together. Subsequently, for each depen- 
dent variable on~'fi4repeated measures analysis of variance 
with contrasts of each time interval with the postoperative 
baseline was used to establish change with time. 
Resu l ts  
Clinical outcome. Demographic, etiologic, and peri- 
operative data are summarized in Table I. At the time 
of this report, 120 patients have reached the 2-year 
follow-up interval, 57 patients have reached the 3-year 
mark, and 14 have reached the 4-year mark. Although 
84% of patients were in New York Heart Association 
functional classes II and III before operation, these 
proportions had changed to 92% in class I, 7% in class 
II, 1% in class III, and 0% in class IV at 3 to 6 months. 
At 1 year and at later visits, 99% or more patients were 
in classes I and II, with most being in class I. 
Table II provides complication rates. There were 
two endocarditis events (both late), two patients 
had anticoagulant-related hemorrhages (both 
late), four had myocardial infarctions (three early, 
one late), and one had thrombosis (late, endocar- 
ditis-related) event. In addition, there were 11 
thromboembolic events (four early and seven 
late), all of which were neurologic (transient 
ischemic attack or stroke). 
There were nine deaths (one early and eight late) 
in this cohort, three of which were valve related. 
Two patients died of bacterial endocarditis (at 34 
and 42 postoperative days), and one patient died of 
intracerebral hemorrhage 20 months after opera- 
tion. This patient was receiving warfarin (coumadin) 
because of a previous transient ischemic attack. The 
six non-valve-related deaths were caused by right 
ventricular infarction from injury to the right coro- 
nary artery (at 2 days), cardiac arrhythmia or arrest 
(at 58 days), suicide (at 80 days), myocardial infarc- 
tion from concomitant a herosclerosis (at 143 days), 
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Aortic valve disease tiology 
Calcification 177 69.6% 
Congenital defect 100 39.3% 
Rheumatic disease 29 11.4% 
Endocarditis 4 1.5% 
Structural deterioration 1 0.3% 
Prosthesis dysfunction 7 2.7% 
Other etiology 6 2.3% 
Sex 
Female 84 32.3% 
Male 170 67.7% 
Age group (yr) 
<40 19 7.5% 
40-49 25 9.8% 
50-59 43 16.9% 
60-69 103 40.6% 
70-79 60 23.6% 
->80 4 1.6% 
Age (yr) 254 62.1 + 11.6 
Body surface area (m 2) 254 1.9 ± 0.2 
Valve size implanted (ram) 
21 1 0.4% 
22 2 0.8% 
23 24 9.4% 
25 62 24.4% 
27 93 36.6% 
29 72 28.3% 
Preoperative NYHA class 
I 17 6.7% 
II 94 37.0% 
III 120 47.2% 
IV 23 9.1% 
NYHA class at 3-6 months 
I 210 92.1% 
II 16 7.0% 
III 2 0.9% 
IV 0 0.0% 
Initial condition of the anulus 
Normal 10 3.9% 
Stenotic only 198 78.0% 
Enlarged/dilated only 12 4,7% 
Mixed 4 L6% 
Other 2 0,8% 
Unknown 28 11,0% 
Condition of preexisting aortic valve 
Normal 1 0,4% 
Scarred or fibrosed leaflets 125 49,2% 
Leaflet torn or ruptured 12 4.7% 
Calcified leaflets 226 89.0% 
Infection 2 0,8% 
Commissural fusion 65 25.6% 
Bicuspid valve 123 48,4% 
Bioprosthesis dysfunction 2 0.8% 
Other 13 5.1% 
Previous cardiovascular operations 
Coronary artery bypass grafting 4 1.5% 
Permanent pacemaker insertion 5 1.9% 
33.3 93.4 
1.4 2.5 
Tab le  I .  Pat ient  characteristics (IV = 254) 
Mean + SD 
(continuous) or 
Characteristic N % (categoric) Minimum Maximum 
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Table I. Cont'd 
Mean + SD 
(continuous) or 
Characteristic N % (categoric) Minimum Maximum 
Aortic valve repair 0 
Aortic valve replacement 4 
Other cardiovascular operations 7 
Concomitant coronary bypass 83 
Cardiopulmonary bypass time (rain) 
All patients 254 
Patients with no concomitant procedures 160 
Aortic crossclamp time (min) 
All patients 254 
Patients with no concomitant procedures 160 
Anticoagulant and antiplatelet therapies at discharge 253 
Aspirin or other platelet inhibitor 228 
Dipyridamole 7 
Coumadin 11 
None 13 
0.0% 
1.5% 
2.7% 
32.7% 
121.2 _+ 40.0 
109.3 _+ 32.0 
96.3 _+ 40.8 
90.1 _+ 27.7 
90.1% 
2.8% 
4.3% 
5.1% 
58 
58 
46 
46 
277 
190 
253 
171 
SD, Standard eviation; NYHA, New York Heart Association. 
Table II. Complication rates for primary and secondary events* (N = 254 patients) 
Early events (<-30 days) 
Late events (>30 days) 
Event No. Simple % No. Patient-years at risk 
Linearized raw/ 
(%/patient-year; +_ SE) 
Endocarditis 0 0.0 2 522.6 
Anticoagulant-related hemorrhage 0 0.0 2 521.9 
Myocardial infarction 3 1.2 1 516.4 
Thromboembolism 4 1.6 7 499.6 
Thrombosis 0 0.0 1 522.6 
Death (all causes) 1 0.4 8 522.6 
0.4 -+ 0.3 
0.4 +- 0.3 
0.2 -+ 0.2 
1.4 -+ 0.5 
0.2 + 0.2 
1.5 -+ 0.5 
SE, Standard error. 
*Both primary and secondary events are included (e.g., thrombosis secondary to endocarditis would be counted in both event categories). 
tLinearized rates are calculated by dividing the number of events by the patient's years of follow-up × 100%. 
Table I l ia. Severity of aortic insufficiency by visit 
Trivial Mild Moderate 
No. echocardiographic 
Visit examinations N % N % N % 
Sevem 
N % 
Early 248 11 4.4 5 2.0 0 0.0 0 
3-6 month 227 8 3.5 12 5.3 0 0.0 0 
12 months 179 5 2.8 8 4.5 0 0.0 0 
24 months 113 7 6.2 2 1.8 1 0.9 0 
36 months 58 3 5.2 1 1.7 0 0.0 0 
All visits 825 34 4.1 28 3.4 1 0.1 0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
malignancy (at 235 days), and pneumonia (at 612 
days). The Kaplan-Meier freedom from death at 3 
years was 95.9% _+ 1.4% (Fig. 1). 
Eehoeardiographie studies. Transthoracic echo- 
cardiography was used to assess both the clinical 
performance of the valve (leaflet function, insuffi- 
ciency, thrombosis) and the hemodynamics (trans- 
valvular mean gradient and EOA). In the early 
postoperative period, 94% showed no insufficiency; 
Table I I Ib. Severity of aortic insufficiency 
categorization 
Ratio of area 
of jet to area of LVOT 
(short-axis view) 
Ratio of height of 
jet to height of LVOT 
(long-axis view) 
Trivial <4 <24 
Mild 4-<25 24-<45 
Moderate 25-<60 45-<65 
Severe ->60 >-65 
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Table IV. Mean gradient and effective orifice area by postoperative visit 
Mean gradient (mm Hg) 
Valve size (ram) Postoperative visit N Mean +- SD 
EOA (cm 2) 
N Mean +_ SD 
23 Early 24 8.4 _+ 3.8 
3-6 month 22 5.4 _+ 3.4 
12 months 15 5.5 + 2.6 
24 months 7 4.2 _+ 2.2 
36 months 5 4.7 + 4.3 
25 Early 61 6.7 _+ 3.0 
3-6 months 57 5.2 + 2.9 
12 months 45 4.9 _+ 2.8 
24 months 29 4.4 +_ 2.8 
36 months 12 4.4 -- 3.6 
27 Early 86 6.0 _+ 2.6 
3-6 months 79 3.7 _+ 1.9 
12 months 66 3.7 -+ 2.1 
24 months 42 3.0 _+ 1.7 
36 months 20 2.5 +_ 1.4 
29 Early 69 4.8 _+ 2.6 
3-6 months 64 3.2 _+ 1.9 
12 months 50 2.4 + 1.4 
24 months 33 2.4 _+ 1.2 
36 months 19 2.5 +1.2 
All Early 240 6.1 _+ 3.0 
3-6 months 222 4.1 _+ 2.5 
12 months 176 3.8 + 2.4 
24 months 111 3.2 _+ 2.1 
36 months 56 3.1 -+ 2.4 
24 1.29 + 0.42 
21 1.56 + 0.63 
15 1.49 + 0.45 
7 1.55 _+ 0.38 
5 1.80 + 0.84 
60 1.44 + 0.43 
56 1.61 + 0.55 
45 1.70 + 0.78 
29 1.73 _ 0.58 
11 2.22 _+ 1.40 
86 1.64 _+ 0.47 
79 2.06 -+ 0.65 
66 2.12 _+ 0.66 
42 2.33 + 0.71 
20 2.62 + 0.90 
69 2.07 _+ 0.60 
64 2.45 _+ 0.86 
50 2.70 _+ 1.03 
33 2.70 _+ 0.85 
19 2.70 _+ 1.02 
239 1.68 + 0.57 
220 2.01 _+ 0.77 
176 2.12 _+ 0.89 
111 2.23 _+ 0.81 
55 2.49 _+ 1.06 
Data are presented as mean -+ standard deviation. 
Table V. Estimated percentage changes for mean gradient and EOA 
Mean gradient (mm Hg) 
Period % change p for Z statistic 
EOA (cm 2) 
% change p for Z statistic 
Relative change from 
early postoperative 
period to 3-6 months 
Slope from 3-6 
months to 3 years 
(change per period) 
-35.8 (-39.6, -31.7) <0.0001 
-6.1 (-10.1, -2.0) 0.004 
17.2 (12.0, 22.6) <0.0001 
4.4% (1.8%, 7.0%) <0.0001 
The 95% confidence intervals are given in parentheses. 
the other 6% showed trivial or mild insufficiency. At 
subsequent follow-up visits, fewer than 9% of the 
patients showed trivial or mild insufficiency. The 
degree of insufficiency by visit is given in Table III. 
Table IV presents the means of mean systolic gra- 
dient and EOA for each postoperative visit. Table V 
gives the estimated percentage change in mean systolic 
gradient and EOA from early postoperatiVe period to 
3 to 6 months and the trend (slope) for 3 to 6 months 
to 36 months. Overall, the mean gradient decreased 
35.8% in the early postoperative period to 3- to 
6-month period and decreased approximately 6.1% 
each period thereafter. EOA increased 17.2% from 
the early postoperative period to the 3- to 6-month 
period and increased approximately 4.4% each period 
thereafter. All changes were in the direction of im- 
provement and were highly statistically significant. 
Plots of the estimated medians for each valve size are 
given in Figs. 2 through 9. 
Table VI reports the results from the longitudinal 
multiple regression models used to evaluate the effects 
of the covariates. These covariates included valve size, 
hospital where implantation was performed, age at 
implantation, sex, date of implantation, body surface 
area, preoperative New York Heart Association func- 
tional class, whether the valve replaced was stenotic or 
enlarged/dilated before operation, and whether other 
cardiac procedures were performed concomitantly 
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Fig. 8. Change in EOA as a function of time for valve size 27 mm. Numbers of patients at each follow-up 
interval are shown in parentheses. 
with the valve operation. The estimates and 95% 
confidence intervals in Table VI give estimated per- 
centage changes from the postoperative p riod to 3- to 
6-month follow-up interval and estimated percentage 
changes from the 3- to 6-month interval to 3 years for 
mean transvalvular gradient and for EOA. Entries 
marked with asterisks are estimates of statistically 
significant effects included in the model and based on 
the results of the stepwise procedure. Unmarked en- 
tries are estimated effects determined by adding that 
term alone to the stepwise model. None of the covari- 
ate effects are as large as the overall effects. 
Table VII examines the changes in hemodynamics 
and left ventricular mass for patients operated on at 
Sunnybrook Health Science Centre. These data dem- 
onstrate a significant reduction in thickness of both the 
intraventricular septum and the posterior wall of the 
left ventricle from the postoperative p riod to the first 
follow-up visits. These changes resulted in a net de- 
crease in left ventricular mass of 37.8 + 57.9 gm 
(14.3%) and a reduction in left ventricular mass index 
of 21.1 _+ 30.5 gm/m 2(15.2%) during this period. 
Multivariate analysis of variance demonstrated a 
statistically discernible relationship between trans- 
valvular gradient and left ventricular mass through a
1-year period (p < 0.001) in the Sunnybrook subset 
(N = 84). Subsequent univariate analysis of variance 
for each dependent measure stablished robust ef- 
fects for time (up to 1 year) and for each interval 
when compared with the postoperative baseline 
value (p < 0.001 for all). These results during this 
interval replicate the previous analysis on the entire 
cohort (N = 254, Table V). Changes in left ventric- 
ular mass with time are illustrated in Fig. 10. 
Discussion 
This report details the hemodynamic results of 
254 patients enrolled in the ongoing multicenter 
trial of the SPV. The clinical results of a subset of 
these patients are reported elsewhere. I° 
The excellent hemodynamic performance of 
stentless bioprostheses has been repeatedly demon- 
strated by several investigators. 1°'~1'14'17-22 In a 
recent study comparing the SPV with a conventional 
stented heterograft, we demonstrated that it is pos- 
sible to implant significantly arger valves in patients 
matched for body surface area and clinical charac- 
teristics if the SPV is used. 14 In that study, patients 
in whom the SPV was used received a prosthesis on 
average 2.4 sizes larger than that used in patients 
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Fig. 9. Change in EOA as a function of time for valve size 29 mm. Numbers of patients at each follow-up 
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who received conventional stented bioprostheses 
was used. In repeated studies, we have observed that 
postoperative gradients af er AVR with the SPV 
were significantly lower than postoperative gradi- 
ents seen when a conventional stented valve was 
used.ll, 14 The elimination of the stent and sewing 
ring allows the implantation ofa larger bioprosthesis 
in any given root. Furthermore, the leaflets of the 
stentless heterograft may open more fully because 
the commissural reas are pulled apart during sys- 
tole as the sinuses of Valsalva act as the functional 
"stents" for a nonstented bioprosthesis. In compar- 
isons of a stentless valve with a conventional stented 
prosthesis, these differences invalve design probably 
account for the superior hemodynamics in the im- 
mediate postoperative p riod. 
We have also reported that transvalvular g adi- 
ents after AVR with the SPV decrease with time, 
and we hypothesized this was a result of ventricular 
remodeling.a0, 14This study of a much larger group 
of patients confirms our previous results. Follow-up 
serial echocardiograms have demonstrated that the 
postoperative transvalvular g adients decrease with 
time (Table V). It has been suggested that this 
occurrence may be a result of regression of postop- 
erative tissue edema or hematoma, nd it has been 
observed with both the SPY  14 and the Medtronic 
Freestyle m bioprosthesis (Medtronic, Inc., Minne- 
apolis, Minn.) implanted with the partial scallop 
aortic inclusion technique. However, we believe the 
major reason for this decrease ingradients with time 
is ventricular remodeling, and that this remodeling 
is specifically dependent on the unique design of 
stentless bioprostheses. If changes in transvalvular 
gradients were simply a result of resorption of a 
perivalvular hematoma, one would not expect o see 
continued ecreases in the transvalvular gradient 
beyond the arly postoperative period (3 to 6 
months). In contrast, if this phenomenon were de- 
pendent on ventricular remodeling and regression 
of LVH, one would anticipate that continued e- 
creases in transvalvular g adients could extend well 
beyond the early postoperative p riod. Our results 
(Table V) clearly support he latter hypothesis. 
Transvalvular gradient is a function of both the 
velocity in the aorta s well as in the LVOT (Ap- 
pendix). Concentric hypertrophy will decrease the 
size of the LVOT and produce a functional subaor- 
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Table VI. Estimated percentage changes for mean gradient and EOA 
Covariate 
Mean gradient (ram Hg) EOA (cm 2) 
% Change early Slope from % Change early Slope from 
postoperative period 3-6 months postoperative period 3-6 months 
to 3-6 months to 3 years (%) to 3-6 months to 3 years (%) 
Size (mm) 
23 -3  (-15, 10)* 7 ( -3,  18) 
25 13 (3, 24)* -2  ( -8,  5) 
27 -3  (-15, 10)* -3  ( -8,  3) 
29 -4  (-12, 5)* -2  ( -8,  4) 
Toronto Hospital -17  (-26, -7)*  0.2 ( -9,  10) 
Age (yr) -0.08 (-0.57, 0.42)* -0.32 (-0.62, -0.03)* 
Female sex 4 (-9,  19) 4 (-11, 4) 
Date of implantation 0.023 (0.008, 0.038)* 0.012 (0.0006, 0.023)* 
(days) 
BSA (m 2) 11 (-33, 19) 4 (-14, 25) 
Preoperative NYHA class 2 (-5,  9) 2 ( -3,  7) 
Preoperative aortic stenosis -7  (-22, 10) -1  (-10, 9) 
Enlarged or dilated before -22  (-39, -1)*  -13 (-36, 19) 
operation 
Concomitant procedures 3 - ( -8 ,  15) 
1 (-10, 13) -3  (-8,  3) 
-5  (-12, 3) 0 (-4,  3) 
5 ( -2,  13) 2 (-2,  5) 
-1  ( -9,  7) 2 (-2,  5) 
8 ( -2,  19) 1 (-5,  6) 
0.03 (-0.36, 0.41)* 0.28 (0.12, 0.45)* 
-10 ( -18 , -1 )*  2 ( -2,  7) 
-0.018 (-0.029, -0.007)* -0.005 (-0.012, 0.002) 
2 (-22, 34) -5  (-15, 6) 
1 ( -7 ,5)  -1  ( -4,  20) 
7 ( -4,  1) -0.5 ( -6,  5) 
15 (-6,  40) 14 (-8,  40) 
-2  ( -9,  6) 6 ( 14, 3) 0 (-4,  4) 
Point estimates for percentage change, along with 95% confidence intervals are provided in parentheses. If stepwise procedure included slope term in model, 
percentage change from early postoperative period to 3-6 months was always included in model. BSA, Body surface area; NYHA, New York Heart 
Association. 
*Statistically significant changes at c~ = 0.05 (boldface type). 
Table VII. Hemodynamic and left ventricular mass changes for Sunnybrook patients (N = 84) 
Peak gradient Mean gradient L V mass inde~ 
(mm Hg) (mm Hg) EOA (cm 2) IVS (mm) LVpo,, (mm) LVmass (gin) (gm/m 2) 
Postoperative 19.4 +_ 7.7 (81) 11.0 _+ 4.6 (75) 1.81 _+ 0.59 (74) 13.2 _+ 2.5 (66) 12.8 _+ 2.4 (66) 264.7 _+ 96.9 (66) 139.1 _+ 45.3 (66) 
345 months 14.9 ± 6.6 (72) 8.3 + 4.0 (66) 1.96 ± 0.67 (67) 12.1 ± 2.2 (62) 11.4 + 1.9 (62) 223.4 ± 74.7 (62) 118.3 _+ 35.0 (62) 
A (change from -4.7 _+ 6.9 (68) -3.0 _+ 4.0 (60) 0.15 ± 0.42 (60) -1.2 _+ 1.7 (51) -1.4 ± 1.9 (51) -37.8 ± 57.9 (51) -21.i ± 30.5 (51) 
postopera- 
tive) 
95% confidence -6.34, -3.06 -4.01, -1.99 0.04,0.26 -1.67, -0.73 -1.92, -0.88 -53.7, -21.9 (-29.5, - 12.7) 
limit for A 
p <0.0001 <0.0001 0.0092 <0.0001 <0.0001 <0.0001 <0.0001 
All data presented as mean -- standard eviation. The number of patients examined is shown in parentheses. IVS, Thickness of intraventricular septum, 
LVposp thickness of the posterior wall of the left ventricle (LV); A, change in parameter from immediately after operation to first follow-up visit (3-6 months). 
Statistical significance determined by matched pairs t test such that each patient served as his or her own control. 
tic stenosis. By removal of the stimulus for cardiac 
hypertrophy, however, we believe the ventricle un- 
dergoes remodeling. Figs. 2 through 5 and Tables V 
and VI examine the rate of decrease of transvalvular 
gradient for different valve sizes. If gradient de- 
crease is a biologic process, one may hypothesize 
that the rate of gradient regression should be the 
same for all valve sizes, provided that the stimulus to 
induce hypertrophy was successfully blocked in all 
cases. The results demonstrated that although the 
initial gradient is smaller with the larger valve sizes, 
the change in gradient with time is similar across 
valve sizes. By 36 months after operation, mean 
transvalvular gradient becomes physiologic, with an 
average gradient of about 3.1 mm Hg for all valve 
sizes. These results are consistent with the hypoth- 
esis that gradient regression is indeed a biologic 
process and likely the result of remodeling of the 
ventricle after AVR with the SPV. 
Table VI also indicates several significant predic- 
tors of mean gradient and EOA. For mean gradient, 
the valve size 25 mm appeared to be associated with 
a slower decline between the early postoperative 
period and 3 to 6 months than for other sizes. Older 
patients had greater improvements in gradient from 
3 to 6 months to 3 years. In addition, Toronto 
Hospital patients had somewhat greater improve- 
ment in gradient from the early postoperative pe- 
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LV mass  
(gm) 
400 
350 
300 
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50 
0 
t I I I I 
I I I I I 
Time Interval Post-op 3-6 months 1 year 2 years 3 years 
Patients (N) 66 62 35 14 10 
LV mass 264.7+96.9 223.4+74.7 209.7+69.4 210.3+80.4 208.8+76.1 
Maximum 538.4 510.0 397.7 373.0 355.7 
Minimum 97.2 120.8 109.7 113.6 113.6 
p < 0.0001 < 0.0001 0.2 0.6 
Fig. 10. Changes in left ventricular (LV) mass with time. Data presented as mean _+ standard eviation. 
riod to 3 to 6 months than did patients at the 
Sunnybrook Health Science Centre. The extent of 
the change in gradient beyond the initial follow-up 
and extending to 3 years, however, was the same at 
both sites. The initial differences may be related to 
case selection or to case mix. Furthermore, patients 
who underwent implantation later in the study had 
lesser improvements in gradient, which may also be 
the result of different patient enrollment hrough 
time. The decrease in mean gradient was consistent 
across all levels of the remaining covariates. 
For EOA, all valve sizes were associated with 
increases at the same rates, and there were no 
site-dependent differences (Toronto Hospital vs 
Sunnybrook). Surprisingly, older patients had 
greater increases in EOA from 3 to 6 months to 3 
years. Female patients had smaller changes than 
their male counterparts from early postoperative 
period to 3 to 6 months. Likewise, patients with later 
dates of implantation had smaller increases during 
the early postoperative period to 3- to 6-month 
period. The increase in EOA was consistent across 
all levels of the remaining covariates. 
As previously discussed, ventricular hypertrophy 
is a physiologic response to an altered hemodynamic 
state. Animal studies have demonstrated that the 
hypertrophic response is mediated by classic signal 
transduction mechanisms 1' 2, 4-6 involving protoon- 
cogene activation and intracellular signaling through a
classic protein kinase C pathway. 7 The human heart 
has also been shown to undergo molecular adaptation 
to pressure overload. 23 Induction of LVT-I, both in 
experimental models and in human beings, can be 
mediated by the renin-angiotensin system. 24' 25 The 
salient feature of transduction pathways is that to 
maintain the process the signal mechanisms must be 
sustained. If classic transduction pathways are opera- 
tional in the development and maintenance of LVH in 
human beings in response to aortic valve pathology, 
then correction of the valve lesion may not necessarily 
result in resolution of LVH if there is a persistent and 
significant residual transvalvular gradient. On the 
other hand, elimination of or significant reduction in 
transvalvular g adient may abolish the stimulus for the 
maintenance of LVH and subsequently allow ventric- 
ular remodeling and regression of ventricular hyper- 
trophy to occur. 
This hypothesis supported by mathematic mod- 
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els of ventricular geometry and function. Dumesnil 
and coworkers 26 developed a model to study the 
dynamic geometry of the left ventricle. They dem- 
onstrated that ejection fraction not only is depen- 
dent on the contraction of the circumferential nd 
longitudinal fibers of the myocardium but also is 
related to the specific R/h ratio of the ventricle, 
where R is the mid-wall radius and h is the wall 
thickness. This phenomenon is particularly relevant 
when studying ventricles with variable R/h ratios, as 
may occur with LVH. In subsequent work, these 
investigators demonstrated that for two ventricles 
with identical preload the ejection fraction will be 
higher in the ventricle that has undergone LVH 
than in the normal ventricle. 27 These results predict 
that flow velocity across the aortic valve would be 
higher in patients with LVH than in normal patients. 
To extend this concept, a regression of LVH with 
time would result in a decreased flow velocity across 
the valve, which in turn would result in a decrease in 
transvalvular gradient. 
If changes in gradient are indeed the result of 
ventricular remodeling, one would expect to see a 
parallel reduction in left ventricular mass. Our data 
clearly demonstrate a reduction in both left ventric- 
ular mass and in left ventricular mass index with 
time (Table VII). Furthermore, the results of the 
multivariate analysis of variance revealed the pres- 
ence of a statistically discernible relationship be- 
tween transvalvular gradient and left ventricular 
mass as a function of time. In addition, the analysis 
of variance demonstrated that for each of the de- 
pendent measures (left ventricular mass, gradient) 
there was a statistically significant decrease in their 
means through three time intervals (postoperative, 3 
to 6 months, 1 year). Whether left ventricular mass 
regression continues beyond 1 year after AVR with 
the SPV cannot be ascertained from currently avail- 
able data. Finally, our results and hypotheses are 
supported by a recent clinical study demonstrating 
reversal of hypertension-induced LVH with medical 
therapy 2s and by the work of Jin and associates, 29 
who performed a comparative study on patients who 
received an aortic homograft, an SPV, or a conven- 
tional stented prosthesis. Left ventricular mass re- 
gression was comparable in patients receiving SPVs 
and homografts; patients who received a stented 
valve (either tissue or mechanical) did not have the 
same extent of mass regression. 
We believe that valve design may play an impor- 
tant role in these findings. In contrast to the stent- 
less valve, the effective valve orifice in a conven- 
tional stented valve is fixed by the supporting stent 
and sewing ring. Postoperative transvalvular gradi- 
ents are therefore fixed by the supporting ring. This 
point is particularly important if there is a mismatch 
between the valve size and the patient's body size. If 
too small a stented valve is implanted, the residual 
postoperative gradient may be quite significant, 
making regression of hypertrophy and ventricular 
remodeling unlikely. 
Conclusion 
Clinical experience with the SPV to date is en-' 
couraging, and we remain enthusiastic about its use 
as a bioprosthesis. Low-pressure fixation, glutaral- 
dehyde cross-linking, and the stentless design, which 
allows the dissipation of shear forces into the sinuses 
during diastole, may all contribute to an improve- 
ment in valve longevity compared with conventional 
stented valves. Furthermore, the hemodynamic per- 
formance of the valve is excellent and may have 
important prognostic mplications. Persistence ofLVH 
was shown in the Framingham study to be an impor- 
tant predictor of mortality. 3° We believe that the 
unique stentless design of the SPV removes the stim- 
ulus that maintains LVH in aortic valve disease- 
induced hypertrophy, thereby permitting remodeling 
to occur. Despite the slightly increased ifficulty in 
implantation, the initial clinical results have been 
favorable and warrant continued clinical investigation. 
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Discuss ion 
Dr. Delos M. Cosgrove (Cleveland, Ohio). You have 
done an excellent job reporting the hemodynamic perfor- 
mance of the you report little or no aortic regurgitation. 
This is a tribute to the excellent surgery and the surgical 
technique of implantation that has been developed. Sec- 
ondly, you have carefully recorded the hemodynamic 
performance of this new prosthesis, recording both gradi- 
ent and EOA. Unfortunately, the reporting of valve 
gradient is not as useful a descriptor of valve function as 
valve orifice area. This is because the gradient continues 
to increase as flow across the valve increases. Recorded 
valve orifice area data llow us to compare the perfor- 
mance of the currently available bioprostheses. Compar- 
ison by size of the SPV with published data for the 
Carpentier-Edwards standard, supraannular, and pericar- 
dial valves shows that all porcine valves have similar valve 
orifice areas but that the pericardial valve is slightly larger. 
Your data give us the opportunity to compare different 
types of stentless prostheses. A multivariant trial of the 
Prima Edwards stentless valve has recently been pub- 
lished. The EOAs of this valve obtained at 12 months 
compare almost identically with those at 12 months as 
presented today, suggesting that there is little difference 
between these two types of prostheses. 
The third important observation is the report of the 
decreasing left ventricular mass with time. It is well 
recognized that LVH begins to diminish immediately, but 
it has never been so well documented, nor has the fact that 
the majority of the resolution of the hypertrophy takes 
place in the first 6 months to a year been so apparent. 
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Fourth, a major observation has been made that EOA 
and gradient appear to improve with time, with most of 
the change occurring in the first 6 months. A similar trend 
was observed in the published performance of the Prima 
Edwards stentless valve. How is it possible, then, that a 
glutaraldehyde-treated, cloth-enclosed porcine prosthesis 
can increase in size? I suggest that this change is a result of 
changes in the LVOT. Echocardiography depends on mea- 
suring the velocity of flow in the LVOT and the aorta to 
obtain hemodynamic performance of the valve. With reso- 
lution of the hypertrophy, the LVOT enlarges, causing a 
decrease in its velocity. This, I believe, is the reason for the 
changes in the EOA, as opposed to actual changes in the 
valve structure. I would be interested in your thoughts on 
the reasons for this apparent change in EOA with time. 
Dr. Del Rizzo. We actually have looked at what you are 
talking about. I think the answer to your question about 
why the gradients change with time is multifactorial. We 
hypothesized that annular expansion may be part of this 
(J Card Surg 1994;9:379-85), and subsequent reports by 
Dr. Westaby on the Medtronic Freestyle valve (Ann 
Thorac Surg 1995;59:857-62) and by Dr. Mohr on the SPV 
valve (Ann Thorac Surg 1995;60:171-6) suggested that our 
hypothesis may be correct. Furthermore, there is experi- 
mental evidence to suggest that the anulus is a dynamic, 
rather than a static, structure. Work out of the University 
of Western Ontario (London, Ontario, Canada) on an 
isolated porcine heart model (J Cardiovasc Surg 1991;6: 
482-9) has shown that in a heart at normal pressure, in 
contrast o a cardioplegia-arrested h art, the anulus ex- 
pands by approximately 40%. This, I think, is part of the 
answer, but it is not the entire answer. The other part, as 
you alluded to, is changes in hemodynamics. Dr. Dumesnil 
and colleagues from the Quebec Heart Institute looked at 
ventricular geometry and its effect on ejection fraction. 
They demonstrated that for equal volume load, a hyper- 
trophied heart has a higher ejection fraction than a 
normal heart, and that this will translate into a higher 
transvalvular velocity. If this is correct, then changes in 
gradient should follow changes in transvalvular velocity. 
Dr. Dumesnil postulated that transvalvular gradient is 
determined by two factors. One is the EOA, as you 
yourself have pointed out, and the other is the change in 
the transvalvular velocity (Eur J Cardiothorac Surg 
1992[suppl 1]:534-8). We performed a regression analysis 
in which we compared changes in gradient against changes 
in transvalvular velocity, and showed that this was a highly 
significant linear relationship (r = 0.09, p < 0.0001). I
repeated the analysis looking at changes in the cross- 
sectional area of the LVOT versus changes in gradient, 
and also at changes in the velocity within the LVOT 
against changes in gradient, and found no relationship. 
Dr. Colleen F. Sintek (Los Angeles, Calif.). I congratu- 
late you on your large series of patients receiving stentless 
valves and your excellent results. Since January 1993, our 
group has implanted 83 of the Freestyle valves manufac- 
tured by Medtronic, and like you we have seen significant 
decreases in the transvalvular gradients and significant 
increases in the EOAs during the first year of follow-up 
for all valve sizes. In addition, we have seen lesser degrees 
of improvement in hemodynamics between 1 and 2 years. 
We have found this valve to be especially useful in the 
elderly patient with a small aortic root. The excellent 
hemodynamics that we have seen with even the size 19 
valves has allowed us to avoid aortic root enlargement 
procedures in this group of patients in whom we often- 
times see calcification. In fact, one third of our 83 patients 
received size 19 or size 21 valves. I want to say right now 
that we oversized our valves by about 2 mm, so that a 
patient who would get a size 19 stented valve would 
receive a size 21 Freestyle stentless valve. We implanted 
eight size 19 and 21 size 21 valves, with EOAs at 1 year of 
1.3 and 1.6 cm 2, respectively. 
Dr. Pennington. Dr. Sintek, we are interested in your 
information. Do you have any questions? 
Dr. Sintek. Yes, I do. About the size, we really feel that 
the advantage of the stentless valve is in the patient with 
a small aortic root. I was curious that your valve sizes were 
much larger than those in the patients with whom we are 
dealing. Do you think that this is because of a difference in 
our populations? Our average age was 76 years, and most of 
our patients were women. Or do you think it has to do with 
your technique of oversizing significantly? Do you tilt the 
valve? Do you enlarge the aortic roots on your patients? 
Dr. Del Rizzo. I think in part it is the fact that we have 
younger patients and more of our patients are male. That 
may be part of the reason why we are implanting larger 
valves. The other, as I alluded to previously, probably has 
to do with implantation technique. We size the valve to 
the sinotubular junction, rather than to the aortic anulus, 
and this tends to give us a larger size. As I mentioned 
before, we are probably oversizing our valves, which may 
contribute to why we are getting such large valves in. We 
do not tilt the valve, and we do not do an aortic root 
enlargement procedure. 
Appendix 
The mean systolic gradient and EOA are calculated by 
the following equation: 
Mean systolic gradient = 4[(0.65V2)  - (0.65V1) 2] (1) 
0.8 × (0.65VI) x ALVOT X 100 
EOA : (2) 
100 × ,~(0.65V2)  - (0.65V,) 2] 
where V 1 is the maximum velocity in LVOT (m/sec), V e is 
the maximum velocity in the aortic valve (m/sec), D is the 
inner diameter of the LVOT (cm), and ALvor is the area 
of the LVOT (cm2). 
The left ventricular (LV) mass (gin) is calculated by the 
following equation: 
LV mass = 0.00083 [(LVpost + IV8 + LVend) 3 
-- (LVend) 3] -}- 0.6 (3) 
where LVpost is the LV posterior wall thickness at end- 
diastole (ram), IVS is the thickness of the intraventricular 
septum at end-diastole (mm), and LVe,,d is the LV end- 
diastolic size (mm). 
The LV mass index (gm/m 2) is calculated by the follow- 
ing equation: 
LV mass index = LV mass/BSA (4) 
where BSA is the body surface area (m2). 
